A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Lmmunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 21 Apr 2025
At a glance
- Drugs AZD-0305 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 16 Apr 2025 Planned number of patients changed from 99 to 108.
- 27 Feb 2025 Planned number of patients changed from 84 to 99.
- 27 Feb 2025 Planned End Date changed from 11 Nov 2025 to 19 Aug 2026.